A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry

Keith E. Maier, Rohit Jangra, Kevin R. Shieh, David K. Cureton, Hui Xiao, Erik L. Snapp, Sean P. Whelan, Kartik Chandran, Matthew Levy

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Pathogenic New World hemorrhagic fever mammarenaviruses (NWM) utilize Glycoprotein 1 (GP1) to target the apical domain of the human transferrin receptor (hTfR) for facilitating cell entry. However, the conservation between their GP1s is low. Considering this and the slow evolutionary progression of mammals compared to viruses, therapeutic targeting of hTfR provides an attractive avenue for cross-strain inhibition and diminishing the likelihood of escape mutants. Aptamers present unique advantages for the development of inhibitors to vial entry, including ease of synthesis, lack of immunogenicity, and potentially cold-chain breaking solutions to diseases endemic to South America. Here, recognizing that in vivo competition with the natural ligand, transferrin (Tf), likely drove the evolution of GP1 to recognize the apical domain, we performed competitive in vitro selections against hTfR-expressing cells with supplemented Tf. The resultant minimized aptamer, Waz, binds the apical domain of the receptor and inhibits infection of human cells by recombinant NWM in culture (EC50 ≃400 nmol/l). Aptamer multimerization further enhanced inhibition >10-fold (EC50 ≃30 nmol/l). Together, our results highlight the ability to use a competitor to bias the outcome of a selection and demonstrate how avidity effects can be leveraged to enhance both aptamer binding and the potency of viral inhibition.

Original languageEnglish (US)
Pages (from-to)e321
JournalMolecular Therapy - Nucleic Acids
Volume5
DOIs
StatePublished - 2016

Fingerprint

Transferrin Receptors
Fever
Transferrin
Glycoproteins
Endemic Diseases
Refrigeration
South America
Mammals
Ligands
Viruses
Infection
Therapeutics

Keywords

  • aptamer
  • C2.min
  • Junin
  • Machupo
  • mammarenavirus
  • receptor-mediated endocytosis
  • SELEX
  • transferrin receptor
  • Waz

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry. / Maier, Keith E.; Jangra, Rohit; Shieh, Kevin R.; Cureton, David K.; Xiao, Hui; Snapp, Erik L.; Whelan, Sean P.; Chandran, Kartik; Levy, Matthew.

In: Molecular Therapy - Nucleic Acids, Vol. 5, 2016, p. e321.

Research output: Contribution to journalArticle

Maier, Keith E. ; Jangra, Rohit ; Shieh, Kevin R. ; Cureton, David K. ; Xiao, Hui ; Snapp, Erik L. ; Whelan, Sean P. ; Chandran, Kartik ; Levy, Matthew. / A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry. In: Molecular Therapy - Nucleic Acids. 2016 ; Vol. 5. pp. e321.
@article{d601218bfdc94e79af854b20889857bb,
title = "A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry",
abstract = "Pathogenic New World hemorrhagic fever mammarenaviruses (NWM) utilize Glycoprotein 1 (GP1) to target the apical domain of the human transferrin receptor (hTfR) for facilitating cell entry. However, the conservation between their GP1s is low. Considering this and the slow evolutionary progression of mammals compared to viruses, therapeutic targeting of hTfR provides an attractive avenue for cross-strain inhibition and diminishing the likelihood of escape mutants. Aptamers present unique advantages for the development of inhibitors to vial entry, including ease of synthesis, lack of immunogenicity, and potentially cold-chain breaking solutions to diseases endemic to South America. Here, recognizing that in vivo competition with the natural ligand, transferrin (Tf), likely drove the evolution of GP1 to recognize the apical domain, we performed competitive in vitro selections against hTfR-expressing cells with supplemented Tf. The resultant minimized aptamer, Waz, binds the apical domain of the receptor and inhibits infection of human cells by recombinant NWM in culture (EC50 ≃400 nmol/l). Aptamer multimerization further enhanced inhibition >10-fold (EC50 ≃30 nmol/l). Together, our results highlight the ability to use a competitor to bias the outcome of a selection and demonstrate how avidity effects can be leveraged to enhance both aptamer binding and the potency of viral inhibition.",
keywords = "aptamer, C2.min, Junin, Machupo, mammarenavirus, receptor-mediated endocytosis, SELEX, transferrin receptor, Waz",
author = "Maier, {Keith E.} and Rohit Jangra and Shieh, {Kevin R.} and Cureton, {David K.} and Hui Xiao and Snapp, {Erik L.} and Whelan, {Sean P.} and Kartik Chandran and Matthew Levy",
year = "2016",
doi = "10.1038/mtna.2016.32",
language = "English (US)",
volume = "5",
pages = "e321",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A New Transferrin Receptor Aptamer Inhibits New World Hemorrhagic Fever Mammarenavirus Entry

AU - Maier, Keith E.

AU - Jangra, Rohit

AU - Shieh, Kevin R.

AU - Cureton, David K.

AU - Xiao, Hui

AU - Snapp, Erik L.

AU - Whelan, Sean P.

AU - Chandran, Kartik

AU - Levy, Matthew

PY - 2016

Y1 - 2016

N2 - Pathogenic New World hemorrhagic fever mammarenaviruses (NWM) utilize Glycoprotein 1 (GP1) to target the apical domain of the human transferrin receptor (hTfR) for facilitating cell entry. However, the conservation between their GP1s is low. Considering this and the slow evolutionary progression of mammals compared to viruses, therapeutic targeting of hTfR provides an attractive avenue for cross-strain inhibition and diminishing the likelihood of escape mutants. Aptamers present unique advantages for the development of inhibitors to vial entry, including ease of synthesis, lack of immunogenicity, and potentially cold-chain breaking solutions to diseases endemic to South America. Here, recognizing that in vivo competition with the natural ligand, transferrin (Tf), likely drove the evolution of GP1 to recognize the apical domain, we performed competitive in vitro selections against hTfR-expressing cells with supplemented Tf. The resultant minimized aptamer, Waz, binds the apical domain of the receptor and inhibits infection of human cells by recombinant NWM in culture (EC50 ≃400 nmol/l). Aptamer multimerization further enhanced inhibition >10-fold (EC50 ≃30 nmol/l). Together, our results highlight the ability to use a competitor to bias the outcome of a selection and demonstrate how avidity effects can be leveraged to enhance both aptamer binding and the potency of viral inhibition.

AB - Pathogenic New World hemorrhagic fever mammarenaviruses (NWM) utilize Glycoprotein 1 (GP1) to target the apical domain of the human transferrin receptor (hTfR) for facilitating cell entry. However, the conservation between their GP1s is low. Considering this and the slow evolutionary progression of mammals compared to viruses, therapeutic targeting of hTfR provides an attractive avenue for cross-strain inhibition and diminishing the likelihood of escape mutants. Aptamers present unique advantages for the development of inhibitors to vial entry, including ease of synthesis, lack of immunogenicity, and potentially cold-chain breaking solutions to diseases endemic to South America. Here, recognizing that in vivo competition with the natural ligand, transferrin (Tf), likely drove the evolution of GP1 to recognize the apical domain, we performed competitive in vitro selections against hTfR-expressing cells with supplemented Tf. The resultant minimized aptamer, Waz, binds the apical domain of the receptor and inhibits infection of human cells by recombinant NWM in culture (EC50 ≃400 nmol/l). Aptamer multimerization further enhanced inhibition >10-fold (EC50 ≃30 nmol/l). Together, our results highlight the ability to use a competitor to bias the outcome of a selection and demonstrate how avidity effects can be leveraged to enhance both aptamer binding and the potency of viral inhibition.

KW - aptamer

KW - C2.min

KW - Junin

KW - Machupo

KW - mammarenavirus

KW - receptor-mediated endocytosis

KW - SELEX

KW - transferrin receptor

KW - Waz

UR - http://www.scopus.com/inward/record.url?scp=85015218190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015218190&partnerID=8YFLogxK

U2 - 10.1038/mtna.2016.32

DO - 10.1038/mtna.2016.32

M3 - Article

AN - SCOPUS:85015218190

VL - 5

SP - e321

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

ER -